A unique understanding of the combination of anti-CD276 and anti-angiogenesis revealed by using antibody–drug conjugates to ablate CD276+glioma cells concurrently impairing tumour vascular, which was reinforced by the confirmation that CD276 was positively correlated with VEGFA and MMP2. Here, CD276 is linked to central nervous system cancer.